Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lamotrigine · 8 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lamotrigine Extended Release Tablets | EXPERIMENTAL | Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited |
| LAMICTAL XR | ACTIVE_COMPARATOR | (containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC |
| Lamotrigine (chewable, dispersible) | EXPERIMENTAL | Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited |
| Lamictal | ACTIVE_COMPARATOR | Lamictal Tablets 25 mg of Glaxo SmithKline |
| Lamotrigine Tablets 200 mg | EXPERIMENTAL | Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited |
| Lamictal® 200 mg Tablets | ACTIVE_COMPARATOR | Lamictal® 200 mg Tablets of GlaxoSmithKline Inc |
| Name | Type | Description |
|---|---|---|
| Lamotrigine | DRUG | Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg |
| Lamictal® | DRUG | Lamictal® 200 mg Tablets |
Inclusion Criteria: Subjects were selected based on the following inclusion criteria: * Provide written informed consent. * Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg. * Having a body mass index between 18.5 and 24.9 (both inclusive)...